Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.04 USD | -1.18% | +11.01% | -35.30% |
09/04 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
09/04 | Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise | MT |
Sales 2024 * | 2.8M 233M | Sales 2025 * | 32.08M 2.67B | Capitalization | 135M 11.23B |
---|---|---|---|---|---|
Net income 2024 * | -125M -10.42B | Net income 2025 * | -120M -10.01B | EV / Sales 2024 * | 48.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.2 x |
P/E ratio 2024 * |
-1.37
x | P/E ratio 2025 * |
-1.51
x | Employees | 68 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.93% |
Latest transcript on Syros Pharmaceuticals, Inc.
1 day | -1.18% | ||
1 week | +11.01% | ||
Current month | -5.79% | ||
1 month | -19.36% | ||
3 months | -26.64% | ||
6 months | +98.43% | ||
Current year | -35.30% |
Managers | Title | Age | Since |
---|---|---|---|
Conley Chee
CEO | Chief Executive Officer | 54 | 27/21/27 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 01/12/01 |
Jason Haas
DFI | Director of Finance/CFO | 56 | 12/21/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 12/17/12 | |
Tim Tyson
BRD | Director/Board Member | 71 | 16/22/16 |
Marsha Fanucci
BRD | Director/Board Member | 70 | 19/15/19 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 5.04 | -1.18% | 44,534 |
25/24/25 | 5.1 | +0.59% | 128,577 |
24/24/24 | 5.07 | -1.36% | 89,636 |
23/24/23 | 5.14 | +3.01% | 172,679 |
22/24/22 | 4.99 | +9.91% | 151,987 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.30% | 135M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- SYRS Stock